GlassScriptPhysician profile
Muthu V Kumaran
NPI 1003080854
$193,451.18
in general payments reported to CMS, 2019-2025
26 companies · $52K in 2025
The $52K reported for 2025 was more than what 95% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $6,121 · 2021: $12K · 2022: $65K · 2023: $12K · 2024: $33K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $52K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Travel and Lodging: $13K · Food and Beverage: $3,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $52,156.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,573.08 |
| Travel and Lodging | $13,245.96 |
| Food and Beverage | $3,232.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $42,551.71 | 2020-2025 | Tecartus, Yescarta |
| Geron Corporation | $22,138.49 | 2025 | Rytelo |
| Sanofi-Aventis U.S. LLC | $20,204.95 | 2022-2024 | |
| Adc Therapeutics America, INC. | $19,288.38 | 2022 | |
| Incyte Corporation | $17,170.44 | 2024-2025 | Niktimvo, Niktimvo |
| Agios Pharmaceuticals, INC. | $10,909.62 | 2019-2021 | |
| Sobi, INC | $10,589.64 | 2022 | |
| Genzyme Corporation | $8,396.71 | 2022-2025 | |
| Daiichi Sankyo INC. | $7,087.52 | 2024-2025 | Vanflyta |
| Jazz Pharmaceuticals INC. | $6,153.93 | 2019-2021 | |
| Acrotech Biopharma INC. | $5,962.39 | 2022 | |
| Syndax Pharmaceuticals, INC. | $5,255.70 | 2025 | Revuforj |
| Gilead Sciences, INC. | $5,053.92 | 2019-2023 | |
| Genmab U.S., INC. | $3,171.98 | 2025 | Epkinly |
| E.R. Squibb & Sons, L.L.C. | $3,127.88 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $2,036.36 | 2021 | |
| Novartis Pharmaceuticals Corporation | $1,485.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $1,436.80 | 2022-2024 | Imfinzi, Calquence |
| Servier Pharmaceuticals LLC | $1,125.00 | 2021 | |
| Astellas Pharma US INC | $144.99 | 2019-2020 | |
| Celgene Corporation | $125.00 | 2022 | |
| Amgen INC. | $34.77 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muthu Kumaran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.